Top

Quality of Life Research

Published in:

Open Access 01-02-2009

Psychological insulin resistance: patient beliefs and implications for diabetes management

Authors: Meryl Brod, Jens Harald Kongsø, Suzanne Lessard, Torsten L. Christensen

Published in: Quality of Life Research | Issue 1/2009

Abstract

Purpose

To define and understand patient psychological insulin resistance (PIR) and its impact on diabetes management.

Methods

Systematic literature review of peer-refereed journals using the MEDLINE database, including all articles in English from 1985 to 2007. The population included patients with type 1 and type 2 diabetes, insulin naïve, and those currently using insulin. A total of 116 articles were reviewed.

Results

PIR is impacted by patients’ beliefs and knowledge about diabetes and insulin, negative self-perceptions and attitudinal barriers, the fear of side effects and complications from insulin use, as well as lifestyle adaptations, restrictions required by insulin use, and social stigma. These etiological influences, both independently and in combination, constitute a patient’s PIR and may result in the reluctance of patients to both initiate and intensify treatment, leading to delayed treatment initiation and compromised glucose control.

Conclusions

PIR is complex and multifaceted. It plays an important, although often ignored, role in diabetes management. Assisting health care professionals in better understanding PIR from the patient’s perspective should result in improved treatment outcomes. By tailoring treatments to patients’ PIR, clinicians may be better able to help their patients begin insulin treatment sooner and improve compliance, thus facilitating target glycemic control.

Brunton, S. A., Davis, S. N., & Renda, S. M. (2006). Overcoming psychological barriers to insulin use in type 2 diabetes. Clinical Cornerstone, 8(Suppl 2), S19–S26. doi:10.1016/S1098-3597(06)80012-8.PubMed

Riddle, M. C. (2002). The underuse of insulin therapy in North America. Diabetes/Metabolism Research and Reviews, 18, S42–S49. doi:10.1002/dmrr.277.PubMed

United Kingdom Prospective Diabetes Study (UKPDS) Group. (1995). Overview of 6 years’ therapy of type II diabetes: A progressive disease (UKPDS 16). Diabetes, 44, 1249–1258. doi:10.2337/diabetes.44.11.1249.

United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837–853. doi:10.1016/S0140-6736(98)07019-6.

United Kingdom Prospective Diabetes Study (UKPDS) Group. (1999). Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care, 22, 1125–1136. doi:10.2337/diacare.22.7.1125.

Meece, J. (2006). Dispelling myths and removing barriers about insulin in type 2 diabetes. The Diabetes Educator, 32, 9S–18S. doi:10.1177/0145721705285638.PubMed

Fitzgerald, J. T., Gruppen, L. D., Anderson, R. M., Funnell, M. M., Jacober, S. J., Grunberger, G., et al. (2000). The influence of treatment modality and ethnicity on attitudes in type 2 diabetes. Diabetes Care, 23, 313–318. doi:10.2337/diacare.23.3.313.PubMed

Hunt, L. M., Valenzuela, M. A., & Pugh, J. A. (1997). NIDDM patients’ fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care, 20(3), 292–298. doi:10.2337/diacare.20.3.292.PubMed

Zambanini, A., Newson, R. B., Maisey, M., & Feher, M. D. (1999). Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice, 46(3), 239–246. doi:10.1016/S0168-8227(99)00099-6.PubMed

10.

Bogatean, M. P., & Hâncu, N. (2004). People with type 2 diabetes facing the reality of starting insulin therapy: Factors involved in psychological insulin resistance. Practical Diabetes International, 21(7), 247–252. doi:10.1002/pdi.670.

11.

Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005). Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care, 28(10), 2543–2545. doi:10.2337/diacare.28.10.2543.PubMed

12.

Morris, J. E., Povey, R. C., & Street, C. G. (2005). Experiences of people with type 2 diabetes who have changed from oral medication to self-administered insulin injections. Practical Diabetes International, 22(7), 239–243. doi:10.1002/pdi.829.

13.

Centers for Disease Control and Prevention (CDC). (2008). National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997–2003. Data computed by personnel in the Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC. Available online at: http://www.cdc.gov/diabetes/statistics/meduse/table2.htm.

14.

Polonsky, W. H., & Jackson, R. A. (2004). What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clinical Diabetes, 22, 147–150. doi:10.2337/diaclin.22.3.147.

15.

Okazaki, K., Goto, M., Yamamoto, T., Tsujii, S., & Ishii, H. (1999). Barriers and facilitators in relation to starting insulin therapy in type 2 diabetes [abstract]. Diabetes, 48, A1319.

16.

Snoek, F. J., Skovlund, S. E., & Pouwer, F. (2007). Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health and Quality of Life Outcomes, 5, 69. doi:10.1186/1477-7525-5-69.PubMed

17.

Alberti, G. (2002). The DAWN (Diabetes Attitudes, Wishes and Needs) study. Practical Diabetes International, 19(1), 22a–24a. doi:10.1002/pdi.305.

18.

Haque, M., Emerson, S. H., Dennison, C. R., Navsa, M., & Levitt, N. S. (2005). Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. South African Medical Journal, 95(10), 798–802.PubMed

19.

Rubin, R. R., & Peyrot, M. (2001). Psychological issues and treatments for people with diabetes. Journal of Clinical Psychology, 57, 457–478. doi:10.1002/jclp.1041.PubMed

20.

Funnell, M. M. (2007). Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes, 25, 36–38. doi:10.2337/diaclin.25.1.36.

21.

Peragallo-Dittko, V. (2007). Removing barriers to insulin therapy. The Diabetes Educator, 33, 60S–65S. doi:10.1177/0145721707301210.PubMed

22.

Leslie, C. A., Satin-Rapaport, W., Matheson, D., Stone, R., & Enfield, G. (1994). Psychological insulin resistance: A missed diagnosis? Diabetes Spectrum, 7, 52–57.

23.

Ho, E. Y., & James, J. (2006). Cultural barriers to initiating insulin therapy in Chinese people with type 2 diabetes living in Canada. Canadian Journal of Diabetes, 30(4), 390–396.

24.

Kruger, D. F. (2007). The other “insulin resistance”: Overcoming barriers to insulin use and encouraging diabetes self-management. The Diabetes Educator, 33, 80S–81S. (Intro.).PubMed

25.

Kruger, D. F. (2007). Tying it all together: Matching insulin regimens to individual patient needs. The Diabetes Educator, 33, 91S–95S. doi:10.1177/0145721707302060.PubMed

26.

Phillips, P. (2005). Type 2 diabetes—Failure, blame and guilt in the adoption of insulin therapy. The Review of Diabetic Studies: RDS, 2(1), 35–39. doi:10.1900/RDS.2005.2.35. Epub May 10, 2005.PubMed

27.

Davis, S. N., & Renda, S. M. (2006). Psychological insulin resistance: Overcoming barriers to starting insulin therapy. The Diabetes Educator, 32, 146S–152S. doi:10.1177/0145721706289226.PubMed

28.

Funnell, M. M., Kruger, D. F., & Spencer, M. (2004). Self-management support for insulin therapy in type 2 diabetes. The Diabetes Educator, 30, 274–280. doi:10.1177/014572170403000220.PubMed

29.

Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007). Transition to insulin in Type 2 diabetes: Family physicians’ misconceptions of patients’ fears contributes to existing barriers. Journal of Diabetes and its Complications, 21(4), 220–226. doi:10.1016/j.jdiacomp.2006.02.004.PubMed

30.

Korytkowski, M. (2002). When oral agents fail: Practical barriers to starting insulin. International Journal of Obesity and Related Metabolic Disorders, 26(Suppl 3), S18–S24. doi:10.1038/sj.ijo.0802173.PubMed

31.

Wolffenbuttel, B. H., Drossaert, C. H., & Visser, A. P. (1993). Determinants of injecting insulin in elderly patients with type II diabetes mellitus. Patient Education and Counseling, 22(3), 117–125. doi:10.1016/0738-3991(93)90091-A.PubMed

32.

Stotland, N. L. (2006). Overcoming psychological barriers in insulin therapy. Insulin, 1, 38–45. doi:10.1016/S1557-0843(06)80006-0.

33.

Snoeck, F. J. (2001). Psychological insulin resistance. Diabetes Voice, 46(3), 27–28.

34.

Brod, M., Hoomans, E. H. M., & Wiebinga, C. J. (2007). Understanding the impact of controlled ovarian stimulation (COS) on women’s functioning and well-being. Annual meeting of the European Society for Human Reproductive Endocrinology, Lyon, France. Poster presentation.

35.

Carver, C. (2006). Insulin treatment and the problem of weight gain in type 2 diabetes. The Diabetes Educator, 32(6), 910–917. doi:10.1177/0145721706294259.PubMed

36.

Delahanty, L. M., Grant, R. W., Wittenberg, E., Bosch, J. L., Wexler, D. J., Cagliero, E., et al. (2007). Association of diabetes-related emotional distress with diabetes treatment in primary care patients with Type 2 diabetes. Diabetic Medicine, 24(1), 48–54. doi:10.1111/j.1464-5491.2007.02028.x.PubMed

37.

Bryden, K. S., Neil, A., Mayou, R. A., Peveler, R. C., Fairburn, C. G., & Dunger, D. B. (1999). Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care, 22(12), 1956–1960. doi:10.2337/diacare.22.12.1956.PubMed

38.

Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Aponte, J. E., Jacobson, A. M., & Cole, C. F. (1994). Insulin omission in women with IDDM. Diabetes Care, 17, 1178–1185. doi:10.2337/diacare.17.10.1178.PubMed

39.

Albu, J., & Raja-Khan, N. (2003). The management of the obese diabetic patient. Primary Care: Clinics in Office Practice, 30(2), 465–491. doi:10.1016/S0095-4543(03)00043-5.PubMed

40.

Saleh, M., & Grunberger, G. (2001). Hypoglycemia: An excuse for poor glycemic control? Clinical Diabetes, 19(4), 161–167. doi:10.2337/diaclin.19.4.161.

41.

Shiu, A. T., & Wong, R. Y. (2002). Fears and worries associated with hypoglycaemia and diabetes complications: Perceptions and experience of Hong Kong Chinese clients. Journal of Advanced Nursing, 39(2), 155–163. doi:10.1046/j.1365-2648.2002.02255.x.PubMed

42.

Shiu, A. T., Kwan, J. J., & Wong, R. Y. (2003). Social stigma as a barrier to diabetes self-management: Implications for multi-level interventions. Journal of Clinical Nursing, 12(1), 149–150. doi:10.1046/j.1365-2702.2003.00735.x.

43.

Cappelleri, J. C., Gerber, R. A., Kourides, I. A., & Gelfand, R. A. (2000). Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care, 23, 1799–1803. doi:10.2337/diacare.23.12.1799.PubMed

44.

Hayes, R. P., Bowman, L., Monahan, P. O., Marrero, D. G., & McHorney, C. A. (2006). Understanding diabetes medications from the perspective of patients with type 2 diabetes: Prerequisite to medication concordance. The Diabetes Educator, 32(3), 404–414. doi:10.1177/0145721706288182.PubMed

45.

Siddiqui, N. I. (2007). Evaluation of inhaled insulin therapy for diabetes mellitus. Mymensingh Medical Journal, 16(2), 237–245.PubMed

46.

Jani, R., Triplitt, C., Reasner, C., & Defronzo, R. A. (2007). First approved inhaled insulin therapy for diabetes mellitus. Expert Opinion on Drug Delivery, 4(1), 63–76. doi:10.1517/17425247.4.1.63.PubMed

47.

Mudaliar, S. (2007). Inhaled insulin using AERx insulin diabetes management system (AERx iDMS). Expert Opinion on Investigational Drugs, 16(10), 1673–1681. doi:10.1517/13543784.16.10.1673.PubMed

48.

United Kingdom Prospective Diabetes Study (UKPDS) Group. (1995). Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. British Medical Journal, 310, 83–88.

49.

Dietrich, U. C. (1996). Factors influencing the attitudes held by women with type II diabetes: A qualitative study. Patient Education and Counseling, 29, 13–23. doi:10.1016/0738-3991(96)00930-5.PubMed

50.

Skovlund, S. E., Peyrot, M., & DAWN International Advisory Panel. (2005). The Diabetes Attitudes, Wishes, and Needs (DAWN) program: A new approach to improving outcomes of diabetes care. Diabetes Spectrum, 18, 136–142. doi:10.2337/diaspect.18.3.136.

51.

Hauber, A. B., Johnson, F. R., Sauriol, L., & Lescrauwaet, B. (2005). Risking health to avoid injections: Preferences of Canadians with type 2 diabetes. Diabetes Care, 28(9), 2243–2245. doi:10.2337/diacare.28.9.2243.PubMed

52.

Korytkowski, M., Niskanen, L., & Asakura, T. (2005). FlexPen: Addressing issues of confidence and convenience in insulin delivery. Clinical Therapeutics, 27(Suppl B), S89–S100. doi:10.1016/j.clinthera.2005.11.019.PubMed

53.

Lee, W. C., Balu, S., Cobden, D., Joshi, A. V., & Pashos, C. L. (2006). Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clinical Therapeutics, 28(10), 1712–1725. Discussion 1710–1711. doi:10.1016/j.clinthera.2006.10.004.PubMed

54.

Kanakis, S. J., Watts, C., & Leichter, S. B. (2002). The business of insulin pumps in diabetes care: Clinical and economic considerations. Clinical Diabetes, 20, 214–216. doi:10.2337/diaclin.20.4.214.

55.

Ritholz, M. D., Smaldone, A., Lee, J., Castillo, A., Wolpert, H., & Weinger, K. (2007). Perceptions of psychosocial factors and the insulin pump. Diabetes Care, 30(3), 549–554. doi:10.2337/dc06-1755.PubMed

56.

Kølendorf, K., Ross, G. P., Pavlic-Renar, I., Perriello, G., Philotheou, A., Jendle, J., et al. (2006). Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabetic Medicine, 23(7), 729–735. doi:10.1111/j.1464-5491.2006.01862.x.PubMed

57.

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 29(6), 1269–1274. doi:10.2337/dc05-1365.PubMed

58.

De Leeuw, I., Vague, P., Selam, J. L., Skeie, S., Lang, H., Draeger, E., et al. (2005). Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes, Obesity & Metabolism, 7, 73–82. doi:10.1111/j.1463-1326.2004.00363.x.

59.

Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005). Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 28(4), 950–955. doi:10.2337/diacare.28.4.950.PubMed

60.

Haak, T., Tiengo, A., Draeger, E., Suntum, M., & Waldhäusl, W. (2005). Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 7, 56–64. doi:10.1111/j.1463-1326.2004.00373.x.

61.

Raslová, K., Tamer, S. C., Clauson, P., & Karl, D. (2007). Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clinical Drug Investigation, 27(4), 279–285. doi:10.2165/00044011-200727040-00007.PubMed

62.

Funnell, M. M. (2008). Quality of life and insulin therapy in type 2 diabetes mellitus. Insulin, 3, 31–36. doi:10.1016/S1557-0843(08)80009-7.

63.

Snoek, F. J. (2002). Breaking the barriers to optimal glycaemic control—what physicians need to know from patients’ perspectives. International Journal of Clinical Practice. Supplement, 129, 80–84.PubMed

64.

Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., et al.; The International DAWN Advisory Panel. (2005). Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28(11), 2673–2679. doi:10.2337/diacare.28.11.2673.PubMed

65.

Abraira, C., & Duckworth, W. (2003). The need for glycemic trials in type 2 diabetes. Clinical Diabetes, 21(3), 107–111.

66.

Akram, K., Pedersen-Bjergaard, U., Borch-Johnsen, K., & Thorsteinsson, B. (2006). Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: A literature survey. Journal of Diabetes and its Complications, 20, 402–408.PubMed

67.

Almér, L. O., Wollmer, P., Jonson, B., & Troedsson Almér, A. (2002). Insulin inhalation with absorption enhancer at meal-times results in almost normal postprandial insulin profiles. Clinical Physiology and Functional Imaging, 22(3), 218–221.PubMed

68.

Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998). The emergence of triglycerides as a significant independent risk factor in coronary artery disease. European Heart Journal, 19(Suppl M), M8–M14.PubMed

69.

Barnett, A. H., & Bellary, S. (2007). Inhaled human insulin (Exubera): Clinical profile and patient considerations. Vascular Health and Risk Management, 3(1), 83–91.PubMed

70.

Barnett, A. H., Dreyer, M., Lange, P., Serdarevic-Pehar, M.; On Behalf of the Exubera Phase III Study Group. (2006). An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care, 29(8), 1818–1825.PubMed

71.

Bellary, S., & Barnett, A. H. (2006). Inhaled insulin (Exubera): Combining efficacy and convenience. Diabetes & Vascular Disease Research, 3(3), 179–185.

72.

Berlin, I., Bisserbe, J. C., Eiber, R., Balssa, N., Sachon, C., Bosquet, F., et al. (1997). Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care, 20(2), 176–178.PubMed

73.

Black, C., Cummins, E., Royle, P., Philip, S., & Waugh, N. (2007). The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: A systematic review and economic evaluation. Health Technology Assessment, 11(33), 1–126.PubMed

74.

Blaha, M. J., & Elasy, T. A. (2006). Adherence to insulin and the risk of glucose deterioration. Diabetes Care, 29(8), 1982–1983.PubMed

75.

Caballero, A. E. (2007). Cultural competence in diabetes mellitus care: An urgent need. Insulin, 2, 80–91.

76.

Campos, C. (2007). Addressing cultural barriers to the successful use of insulin in hispanics with type 2 diabetes. Southern Medical Journal, 100(8), 812–820.PubMed

77.

Cefalu, W. T. (2001). Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Annals of Medicine, 33(9), 579–586.PubMed

78.

Chesla, C. A., & Chun, K. M. (2005). Accommodating type 2 diabetes in the Chinese American family. Qualitative Health Research, 15(2), 240–255.PubMed

79.

Clark, M. (2007). Psychological insulin resistance: A guide for practice nurses. Journal of Diabetes Nursing, 11(2), 53–56.

80.

Cramer, J. A., Okikawa, J., Bellaire, S., & Clauson, P. (2004). Compliance with inhaled insulin treatment using the AERx iDMS Insulin Diabetes Management System. Diabetes Technology & Therapeutics, 6(6), 800–807.

81.

de Galan, B. E., Simsek, S., Tack, C. J., & Heine, R. J. (2006). Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Netherlands Journal of Medicine, 64(9), 319–325.PubMed

82.

Díez, J. J., & Iglesias, P. (2003). Inhaled insulin—A new therapeutic option in the treatment of diabetes mellitus. Expert Opinion on Pharmacotherapy, 4(2), 191–200.PubMedCrossRef

83.

Dunn, C., & Curran, M. P. (2006). Spotlight on inhaled human insulin (exubera((r))) in diabetes mellitus. Treatments in Endocrinology, 5(5), 329–331.PubMed

84.

Fineberg, S. E. (2006). Diabetes therapy trials with inhaled insulin. Expert Opinion on Investigational Drugs, 15(7), 743–762.PubMed

85.

Freemantle, N., Blonde, L., Duhot, D., Hompesch, M., Eggersten, R., Hobbs, F. D. R., et al. (2005).Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care, 28, 427–428.PubMed

86.

Funnell, M. M. (2006). The Diabetes Attitudes, Wishes, and Needs (DAWN) study. Clinical Diabetes, 24, 154–155.

87.

Garg, S., Rosenstock, J., Silverman, B. L., Sun, B., Konkoy, C. S., de la Peña, A., et al. (2006). Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia, 49(5), 891–899. Epub Feb 28, 2006.PubMed

88.

Gerber, R. A., Cappelleri, J. C., Kourides, I. A., & Gelfand, R. A. (2001). Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: A randomized controlled trial. Diabetes Care, 24(9), 1556–1559.PubMed

89.

Harris, M. I., Eastman, R. C., Cowie, C. C., Flegal, K., & Eberhardt, M. S. (1999). Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care, 22, 403–408.PubMed

90.

Hermansen, K., & Davies, M. (2007). Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes, Obesity and Metabolism, 9, 209–217.PubMed

91.

Hollander, P. A., Blonde, L., Rowe, R., Mehta, A. E., Milburn, J. L., Hershon, K. S., et al. (2004). Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care, 27(10), 2356–2362.PubMed

92.

Hunt, L. M., Arar, N. H., Larme, A. C., Rankin, S. H., & Anderson, R. M. (1998). Contrasting patient and practitioner perspectives in type 2 diabetes management. Western Journal of Nursing Research, 20(6), 656–682.PubMed

93.

Leichter, S. B. (2005). Problems that extend visit time and cost in diabetes care: 1. How depression may affect the efficacy and cost of care of diabetic patients. Clinical Diabetes, 23(2), 53–54.

94.

Martinez, L., Consoli, S. M., Monnier, L., Simon, D., Wong, O., Yomtov, B., et al. (2007). Studying the Hurdles of Insulin Prescription (SHIP): Development, scoring and initial validation of a new self-administered questionnaire. Health and Quality of Life Outcomes, 5, 53.PubMed

95.

McAuley, L. (2001). Inhaled insulin for the treatment of diabetes mellitus. Issues in Emerging Health Technologies, 18, 1–4.PubMed

96.

Mollema, E. D., Snoek, F. J., Pouwer, F., Heine, R. J., & van der Ploeg, H. M. (2000). Diabetes Fear of Injecting and Self-Testing Questionnaire: A psychometric evaluation. Diabetes Care, 23, 765–769.PubMed

97.

Odegard, P. S., & Capoccia, K. (2007). Medication taking and diabetes: a systematic review of the literature. The Diabetes Educator, 33(6), 1014–1029. Discussion 1030–1031.PubMed

98.

Petrak, F., Stridde, E., Leverkus, F., Crispin, A. A., Forst, T., & Pfutzner, A. (2007). Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care, 30(9), 2199–2204.PubMed

99.

Peyrot, M., Rubin, R. R., & Siminerio, L. M. (2006). Physician and nurse use of psychosocial strategies in diabetes care: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care, 29(6), 1256–1262.PubMed

100.

Polonsky, W. H., Fisher, L., Dowe, S., & Edelman, S. (2003). Why do patients resist insulin therapy? [abstract]. Diabetes, 52, A417.

101.

Rave, K., Bott, S., Heinemann, L., Sha, S., Becker, R. H., Willavize, S. A., et al. (2005). Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care, 28(5), 1077–1082.PubMed

102.

Rosenstock, J., Cappelleri, J. C., Bolinder, B., & Gerber, R. A. (2004). Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care, 27(6), 1318–1323.PubMed

103.

Rosenstock, J., Muchmore, D., Swanson, D., & Schmitke, J. (2007). AIR Inhaled Insulin System: A novel insulin-delivery system for patients with diabetes. Expert Review of Medical Devices, 4(5), 683–692.PubMed

104.

Sadri, H., MacKeigan, L. D., Leiter, L. A., & Einarson, T. R. (2005). Willingness to pay for inhaled insulin: A contingent valuation approach. Pharmacoeconomics, 23(12), 1215–1227.PubMed

105.

Siminerio, L. (2006). Challenges and strategies for moving patients to injectable medications. The Diabetes Educator, 32(Suppl 2), 82S–90S.

106.

Skovlund, S. E., van der Ven, N., Pouwer, F., & Snoek, F. J. (2003). Appraisal of insulin treatment in type 2 diabetes patients with and without previous experience of insulin therapy [abstract]. Diabetes, 52, A419.

107.

Skyler, J. S., Jovanovic, L., Klioze, S., Reis, J., & Duggan, W.; Inhaled Human Insulin Type 1 Diabetes Study Group. (2007). Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care, 30(3), 579–585.PubMed

108.

Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321, 405–412.PubMed

109.

Vinik, A. (2007). Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clinical Therapeutics, 29, 1236–1253.

110.

White, J. R., Davis, S. N., Cooppan, R., Davidson, M. B., Mulcahy, K., Manko, G. A., et al. (2003). Clarifying the role of insulin in type 2 diabetes management. Clinical Diabetes, 21, 14–21.

Title: Psychological insulin resistance: patient beliefs and implications for diabetes management
Authors: Meryl Brod
Jens Harald Kongsø
Suzanne Lessard
Torsten L. Christensen
Publication date: 01-02-2009
Publisher: Springer Netherlands
Published in: Quality of Life Research / Issue 1/2009
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-008-9419-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Psychological insulin resistance: patient beliefs and implications for diabetes management

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Quality of life and self-esteem of persons with paraplegia living in São Paulo, Brazil

Additional psychometric information and vision-specific questionnaires are available for age-related macular degeneration

Comparing SF-6D and EQ-5D utilities across groups differing in health status

Logistics of collecting patient-reported outcomes (PROs) in clinical practice: an overview and practical examples

Importance of patient-centered care in enhancing patient well-being: a cancer survivor’s perspective

Neuroticism and extraversion in association with quality of life in patients with Parkinson’s disease